FabRx
FabRx is a specialist biotech company developing 3D printing technology for fabricating personalized pharmaceuticals and medical devices.
- CEO / Founder
- Álvaro Goyanes
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $825K
- Latest Round
- Grant
- Key Investors
- Innovate UK (non-dilutive)
Technology & Products
Key Products
FabRx provides pharmaceutical 3D printers, software, and pharma-ink development services for personalized medicine and small batch manufacturing. Their offerings include compounding technology and pharmacy automation solutions.
Technological Advantage
Proprietary formulations enabling controlled drug release; bootstrapped to £1M+ revenue without VC funding
Differentiation
Value Proposition
Enables personalized medicine through 3D printed pills with customized dosages and drug release profiles.
How They Differentiate
Only commercially available 3D printer with pharmaceutical-grade certification and hospital deployment
Market & Competition
Target Customers
Hospitals, pharmacies, pharmaceutical companies, research institutions
Industry Verticals
Pharmaceuticals, Healthcare, Personalized Medicine
Competitors
Aprecia (Spritam), Laxxon Medical, MERCK
Growth & Milestones
Growth Metrics
Bootstrapped + non-dilutive (Innovate UK grant) to date; no public equity round closed as of mid-2026; LinkedIn company size 11-50 (HQ London; also Spain/US entities); M3DIMAKER operating in 25+ countries; ~$1M estimated revenue (prior estimate retained, not re-verified)
Major Milestones
2014: Founded as UCL spinout; 2019: Won £600K+ Innovate UK grant (with Katjes Fassin); 2020: Launched M3DIMAKER pharmaceutical 3D printer; 2023: Launched FABRX·AI (Spain); 2024: Launched FABRX US; first community pharmacy (Madrid) dispensed personalised 3D-printed medicines; 2025: Pete Pharma US partnership for compounding pharmacies; Pfizer early-stage clinical-trial batch manufacturing collaboration; 2026: King's Award for Enterprise in Innovation (announced May 2026); EMA published pharmaceutical 3D printing guidance (Mar 2026) with FABRX engagement
Notable Customers
Hospital pharmacies (e.g. Gustave Roussy, Great Ormond Street, Vall d'Hebron); US compounding pharmacies via Pete Pharma (e.g. RX3, Simply Pure Rx, Nextgenrx); research labs and clinical sites globally; community pharmacy deployments (Madrid 2024 first dispensation); Katjes Fassin (historical Innovate UK project)
Equipment deals on record
Publicly disclosed purchases or installs only.
- AM equipment systemBuyer: Université de Liège · Supplier: FABRX ltd